Direkt zum Inhalt
Merck

Y0001586

Atomoxetin -hydrochlorid

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

(R)-Tomoxetin -hydrochlorid, (R)-N-Methyl-γ-(2-methyl­phenoxy)-benzolpropanamin -hydrochlorid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C17H21NO · HCl
CAS-Nummer:
Molekulargewicht:
291.82
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

atomoxetine

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChIKey

LUCXVPAZUDVVBT-UNTBIKODSA-N

Angaben zum Gen

human ... SLC6A2(6530)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Atomoxetine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Norepinephrine uptake blocker.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Irene Joy I Dela Peña et al.
Progress in neuro-psychopharmacology & biological psychiatry, 88, 311-319 (2018-08-21)
Attention-deficit/hyperactivity disorder (ADHD) is a heterogeneous neurodevelopmental disorder characterized by varying levels of hyperactivity, inattention, and impulsivity. Patients with ADHD are often classified as (1) predominantly hyperactive-impulsive, (2) predominantly inattentive, and (3) combined type. There is a growing interest in
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, et al.
European Neuropsychopharmacology, 19(11), 822-834 (2009)
METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ATOMOXETINE HYDROCHLORIDE IN BULK AND CAPSULE DOSAGE FORM BY RP-HPLC.
Swathi G, et al.
World Journal of Pharmacy and Pharmaceutical Sciences (2015)
Dylan Chou et al.
Experimental neurology, 255, 19-29 (2014-03-04)
Fear conditioning in animals has been used extensively to model clinical anxiety disorders. While individual animals exhibit marked differences in their propensity to undergo fear conditioning, the physiologically relevant mediators have not yet been fully characterized. Here, we demonstrate that
Atomoxetine-induced wake-time teeth clenching and sleep bruxism in a child patient.
Kayhan Bahali et al.
European child & adolescent psychiatry, 23(12), 1233-1235 (2014-08-28)

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.